These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [Detection of phosphotyrosine in bcr-abl-positive cells with PY20 antibody and its clinical applications]. Zhu HH; Liu YR; Qin YZ; Chang Y; Li JL; Ruan GR; Jiang B; Chen SS; Lu DP Zhonghua Xue Ye Xue Za Zhi; 2006 Jul; 27(7):441-4. PubMed ID: 17147244 [TBL] [Abstract][Full Text] [Related]
4. A novel FRET-based biosensor for the measurement of BCR-ABL activity and its response to drugs in living cells. Mizutani T; Kondo T; Darmanin S; Tsuda M; Tanaka S; Tobiume M; Asaka M; Ohba Y Clin Cancer Res; 2010 Aug; 16(15):3964-75. PubMed ID: 20670950 [TBL] [Abstract][Full Text] [Related]
5. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation. Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172 [TBL] [Abstract][Full Text] [Related]
7. Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway. Kurosu T; Ohki M; Wu N; Kagechika H; Miura O Cancer Res; 2009 May; 69(9):3927-36. PubMed ID: 19366808 [TBL] [Abstract][Full Text] [Related]
8. The novel pyrrolo-1,5-benzoxazepine, PBOX-21, potentiates the apoptotic efficacy of STI571 (imatinib mesylate) in human chronic myeloid leukaemia cells. Bright SA; Greene LM; Greene TF; Campiani G; Butini S; Brindisi M; Lawler M; Meegan MJ; Williams DC; Zisterer DM Biochem Pharmacol; 2009 Feb; 77(3):310-21. PubMed ID: 19014913 [TBL] [Abstract][Full Text] [Related]
9. N-acetyl cysteine enhances imatinib-induced apoptosis of Bcr-Abl+ cells by endothelial nitric oxide synthase-mediated production of nitric oxide. Rakshit S; Bagchi J; Mandal L; Paul K; Ganguly D; Bhattacharjee S; Ghosh M; Biswas N; Chaudhuri U; Bandyopadhyay S Apoptosis; 2009 Mar; 14(3):298-308. PubMed ID: 19153832 [TBL] [Abstract][Full Text] [Related]
10. [Effect of G-CSF on the proliferation and differentiation of bcr/abl(+)-CD34+ cells from CML patients]. Li CY; Meng FY; Sun QX; Fu YB; Jiang QL; Yi ZS; Song LL Zhonghua Xue Ye Xue Za Zhi; 2007 Nov; 28(11):762-5. PubMed ID: 18457269 [TBL] [Abstract][Full Text] [Related]
11. p210(Bcr-Abl) desensitizes Cdc42 GTPase signaling for SDF-1alpha-directed migration in chronic myeloid leukemia cells. Chang YC; Tien SC; Tien HF; Zhang H; Bokoch GM; Chang ZF Oncogene; 2009 Nov; 28(46):4105-15. PubMed ID: 19718053 [TBL] [Abstract][Full Text] [Related]
12. BCR/ABL P190 transgenic mice develop leukemia in the absence of Crkl. Hemmeryckx B; Reichert A; Watanabe M; Kaartinen V; de Jong R; Pattengale PK; Groffen J; Heisterkamp N Oncogene; 2002 May; 21(20):3225-31. PubMed ID: 12082638 [TBL] [Abstract][Full Text] [Related]
13. Reduction of BCR-ABL1 mutant clones after discontinuation of TKI therapy. Beel K; Janssens A; Verhoef G; Vandenberghe P Leuk Res; 2009 Dec; 33(12):1703-5. PubMed ID: 19457553 [TBL] [Abstract][Full Text] [Related]
14. Modulation of caspase-independent cell death leads to resensitization of imatinib mesylate-resistant cells. Lavallard VJ; Pradelli LA; Paul A; Bénéteau M; Jacquel A; Auberger P; Ricci JE Cancer Res; 2009 Apr; 69(7):3013-20. PubMed ID: 19318579 [TBL] [Abstract][Full Text] [Related]
15. Sensitization of imatinib-resistant CML cells to TRAIL-induced apoptosis is mediated through down-regulation of Bcr-Abl as well as c-FLIP. Park SJ; Kim MJ; Kim HB; Kang CD; Kim SH Biochem J; 2009 Apr; 420(1):73-81. PubMed ID: 19203346 [TBL] [Abstract][Full Text] [Related]
16. 14-3-3 ligand prevents nuclear import of c-ABL protein in chronic myeloid leukemia. Mancini M; Veljkovic N; Corradi V; Zuffa E; Corrado P; Pagnotta E; Martinelli G; Barbieri E; Santucci MA Traffic; 2009 Jun; 10(6):637-47. PubMed ID: 19220809 [TBL] [Abstract][Full Text] [Related]
17. [Molecular design and biological activity of BCR-ABL tyrosine kinase inhibitors]. Peng H; Qi J; Huang N; Xie P; Wang JX; Yang CZ Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2004 Apr; 26(2):145-9. PubMed ID: 15171550 [TBL] [Abstract][Full Text] [Related]
18. Rapid detection of BCR-ABL fusion genes using a novel combined LUX primer, in-cell RT-PCR and flow cytometric method. Shi Y; Li LZ; Sun JZ; Zhang T; Peng J; Xu CG Ann Hematol; 2008 Jan; 87(1):35-41. PubMed ID: 17846772 [TBL] [Abstract][Full Text] [Related]
19. T cell recognition of bcr/abl in healthy donors and in patients with chronic myeloid leukaemia. Westermann J; Schlimper C; Richter G; Mohm J; Dörken B; Pezzutto A Br J Haematol; 2004 Apr; 125(2):213-6. PubMed ID: 15059144 [TBL] [Abstract][Full Text] [Related]
20. Anti-leukemic activity of valproic acid and imatinib mesylate on human Ph+ ALL and CML cells in vitro. Kircher B; Schumacher P; Petzer A; Hoflehner E; Haun M; Wolf AM; Nachbaur D; Gastl G Eur J Haematol; 2009 Jul; 83(1):48-56. PubMed ID: 19226363 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]